

European Heart Journal

Volume 43 No. 27 July 2022

ISSUE @ A GLANCE



Heart failure: how to optimize guideline-directed medical therapy

F. Crea

2533

CardioPulse

The athlete's heart from Philippides to the modern marathon runners

S. Castelletti and G.E. Pieles

2538

Sports cardiology in Europe from the ancient Greek-Roman era to the present

S. Castelletti, F. D'Ascenzi, and M. Papadakis

2542

Meeting challenges with meetings tailored to challenging times: the ESC Acute CardioVascular Care Congress, March 2022

J. Ozkan

2545

Weekly Journal Scan

Placing the risk of myopericarditis following COVID-19 vaccination into perspective

G. Liuzzo and C. Patrono

2547

FOCUS ISSUE ON HEART FAILURE AND CARDIOMYOPATHIES

STATE OF THE ART REVIEW



Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies

S. Frantz, M.J. Hundertmark, J. Schulz-Menger, F.M. Bengel, and J. Bauersachs

2549

META-ANALYSIS

A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer

C. Lewinter, T.H. Nielsen, L.R. Edfors, C. Linde, J.M. Bland, M.M. LeWinter, J.G.F. Cleland, L. Køber, F. Braunschweig, and A. Mansson-Broberg

2562

Editorial

Cardioprotection in breast cancer patients: one size fits all?

G. Gulati

2570

CLINICAL RESEARCH



Accelerated and personalized therapy for heart failure with reduced ejection fraction

L. Shen, P.S. Jhund, K.F. Docherty, M. Vaduganathan, M.C. Petrie, A.S. Desai, L. Køber, M. Schou, M. Packer, S.D. Solomon, X. Zhang, and J.J.V. McMurray

2573

Editorial

Heart failure medication: moving from evidence generation to implementation

J. Tromp and A.A. Voors

2588



Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project

M. Hadwiger, N. Dages, J. Haug, M. Wolf, U. Marschall, J. Tijssen, A. Katalinic, F.-S. Friellitz, and G. Hindricks

2591

Editorial

CRT-P or CRT-D in heart failure patients: the RESET-CRT project—a prelude to the randomized controlled RESET-CRT study

C. Linde

2600

The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic

M.R. Zile, A.S. Desai, M.R. Costanzo, A. Ducharme, A. Maisel, M.R. Mehra, S. Paul, S.F. Sears, F. Smart, C. Chien, A. Guha, J.L. Guichard, S. Hall, O. Jonsson, N. Johnson, P. Sood, J. Henderson, P.B. Adamson, and J. Lindenfeld

2603

Editorial

The COVID-19 pandemic and heart failure: lessons from GUIDE-HF

M.R. Cowie and J.G.F. Cleland

2619

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis

S. Law, M. Bezard, A. Petrie, L. Chacko, O.C. Cohen, S. Ravichandran, O. Ogunbiyi, M. Kharoubi, S. Ganeshanathan, S. Ganeshanathan, J.A. Gilbertson, D. Rowczenio, A. Wechalekar, A. Martinez-Naharro, H.J. Lachmann, C.J. Whelan, D.F. Hutt, P.N. Hawkins, T. Damy, M. Fontana, and J.D. Gillmore

2622

Editorial

Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities

C. Rapezzi, M. Serenelli, and A. Aimo

2633

DISCUSSION FORUM

A laboratory viewpoint of the consensus paper from the European Society of Cardiology regarding the utilization of the American College of Medical Genetics and Genomics pathogenic criteria for cardiomyopathy

Y. Ma, H. Yang, and Z. Li

2636

Interpretation of genetic variants depends on a clinically guided integration of phenotype and molecular data

E. Arbustini, M. Urtis, and P. Elliott

2638

CARDIOVASCULAR FLASHLIGHT

Acute necrotizing eosinophilic myocarditis after COVID-19 vaccination

K. Ohtani, S. Takahama, S. Kato, and T. Higo

2640

Doubly committed ventricular septal defect closure using an eccentric occluder via minimal incision in the anterior median sternum through the left parasternal third intercostal space

X. Lu, P. Wen, and Q. Xing

2641

logical -
modelling
such as
sex, etc.
Despite -
Worsen
EDITOR'S
CHOICE

This paper is Editor's Choice and is available free online at <https://academic.oup.com/eurheartj>

Frantz et al.

to patients

Living M

developing

Cardio

Vance, 9

effects of

(ARBs), an-

metuzumab

Meta-Anal

meta-analy

systematic

non due to

with bre

Published by

Oxford Univer

Published by

</div